This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Ferry Ossendorp, PhD
Professor in Synthetic Vaccine Biology at Leiden University Medical Center


Ferry Ossendorp is heading the Tumor Immunology Group in the Leiden University Medical Center, The Netherlands.

He is Professor in Cancer Vaccine Biology and current research is focusing on improving immunotherapy of cancer. Dendritic cells are studied to optimally induce T cell immunity against tumor antigens by effective antigen targeting, processing and MHC presentation. The tumor microenvironment is studied in cellular and molecular detail. Aim is to modulate immune suppression by using specific antibodies and drugs to improve cancer immunotherapy. Synthetic peptides conjugated to Toll like receptor ligands are currently explored in phase I clinical studies in cancer patients.